logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12391671 B1

PDFFull Text
Date of Patent:
Aug. 19, 2025

Filed:

May. 10, 2022

Allosteric egfr inhibitors and methods of use thereof

Applicant:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

David A. Scott, Newton, MA (US);

David Heppner, Brookline, MA (US);

Thomas Gero, Stow, MA (US);

Courtney A. Cullis, Bedford, MA (US);

Ciric To, Medford, MA (US);

Shih-Chung Huang, Lexington, MA (US);

Yongbo Hu, Winchester, MA (US);

Steve Stroud, Cambridge, MA (US);

Tyler Beyett, Brookline, MA (US);

Michael Eck, Brookline, MA (US);

Nathanael S. Gray, Jamaica Plain, MA (US);

Assignee:

Dana-Farber Cancer Institute, Inc., Boston, MA (US);

Attorney:

Nielsen IP Law LLC

Primary Examiner:

Kortney L Klinkel

Assistant Examiner:

Alison Azar Salamatian

Int. Cl.
CPC ...
A61K 31/4184 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/4725 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/52 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 403/06 (2006.01); C07D 403/14 (2006.01); C07D 471/04 (2006.01); C07D 473/00 (2006.01); C07D 487/04 (2006.01); C07D 495/14 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); C07D 471/04 (2013.01); C07D 473/00 (2013.01); C07D 495/14 (2013.01);
Abstract

The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

Find Patent Forward Citations

Loading…